To evaluate the safety and efficacy of 1 470 nm laser tri-lobe resection in the treatment of high-risk benign prostatic hyperplasia (BPH) with reduced volume excision.

The clinical data of 113 patients with high-risk BPH treated by the 1 470 nm laser tri-lobe resection, that is, the mass resection of the middle and bilateral hyperplasia glands of the prostate, were reviewed and analyzed from April 2019 to October 2022. The patient's general condition, operation duration, indwelling catheterization time, etc. were analyzed, and the preoperative and postoperative IPSS score, residual urine output (RUV), urine flow rate (Q_max) and other indicators were compared.

All patients were completed the operation successfully. There was no intraoperative or postoperative blood transfusion. Operation time, decreased value of hemoglobin, bladder irrigation time, indwelling catheter time and hospitalization time were (41.6±15.3) min, (1.1±0.8) g/L, (1.3±0.2) d, (1.7±0.3) d and (5.5±1.2) d respectively. The postoperative IPSS score, QOL score, RUV and Q_max score of 109 cases were significantly better than those before operation (P<0.05). The improvement of urination was not obvious in 4 cases, whose prostate volume were <40 ml.

1 470 nm laser tri-lobe resection has the advantages of minimal trauma, less bleeding, rapid recovery, good efficacy and other advantages. It's suitable for elderly high-risk BPH patients with large prostate volume.